RO5126766 for Patients With Advanced KRAS-Mutant Lung Cancer

NCT03681483 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

15

Enrollment

OTHER

Sponsor class

Conditions

Advanced Non-small Cell Lung Cancer

Interventions

DRUG: RO5126766

Sponsor

Memorial Sloan Kettering Cancer Center

Collaborators

[object Object]
[object Object]